Take­da wins FDA ap­proval for self-ad­min­is­tered, sub­cu­ta­neous En­tyvio in ul­cer­a­tive col­i­tis

The FDA has ap­proved a sub­cu­ta­neous ver­sion of Take­da’s ul­cer­a­tive col­i­tis drug En­tyvio, more than three years af­ter re­ject­ing the com­pa­ny’s ap­pli­ca­tion over what it said were is­sues re­lat­ed to the de­sign and la­bel­ing of the de­vice.

The drug will be avail­able as a sin­gle-dose pre-filled pen by the end of Oc­to­ber. It’s ap­proved for use af­ter in­duc­tion ther­a­py with in­tra­venous En­tyvio (vedolizum­ab), Take­da an­nounced Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER